Glycosylation in Renal Cell Carcinoma: Mechanisms and Clinical Implications

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Aug 26

PMID 36010674

Authors

Xinqing Zhu

Abdullah Al-Danakh

Lin Zhang

Xiaoxin Sun

Yuli Jian

Haotian Wu

Dan Feng

Shujing Wang

Deyong Yang

Affiliations

Soon will be listed here.

Abstract

Renal cell carcinoma (RCC) is one of the most prevalent malignant tumors of the urinary system, accounting for around 2% of all cancer diagnoses and deaths worldwide. Clear cell RCC (ccRCC) is the most prevalent and aggressive histology with an unfavorable prognosis and inadequate treatment. Patients' progression-free survival is considerably improved by surgery; however, 30% of patients develop metastases following surgery. Identifying novel targets and molecular markers for RCC prognostic detection is crucial for more accurate clinical diagnosis and therapy. Glycosylation is a critical post-translational modification (PMT) for cancer cell growth, migration, and invasion, involving the transfer of glycosyl moieties to specific amino acid residues in proteins to form glycosidic bonds through the activity of glycosyltransferases. Most cancers, including RCC, undergo glycosylation changes such as branching, sialylation, and fucosylation. In this review, we discuss the latest findings on the significance of aberrant glycans in the initiation, development, and progression of RCC. The potential biomarkers of altered glycans for the diagnosis and their implications in RCC have been further highlighted.

Citing Articles

K-Means Clustering of Hyperpolarised C-MRI Identifies Intratumoral Perfusion/Metabolism Mismatch in Renal Cell Carcinoma as the Best Predictor of the Highest Grade.

Horvat-Menih I, Khan A, McLean M, Duarte J, Serrao E, Ursprung S Cancers (Basel). 2025; 17(4).

PMID: 40002163 PMC: 11852806. DOI: 10.3390/cancers17040569.

Comprehensive analysis of α2,3-sialyltransferases as prognostic biomarkers and immunotherapy targets in kidney renal clear cell carcinoma.

Jian Y, Yang K, Li J, Tang L, Zeng G, Sun X Cancer Cell Int. 2025; 25(1):36.

PMID: 39920744 PMC: 11806589. DOI: 10.1186/s12935-025-03640-1.

Post-translational modifications and bronchopulmonary dysplasia.

Yang K, He T, Sun X, Dong W Front Pediatr. 2025; 12():1426030.

PMID: 39830627 PMC: 11738936. DOI: 10.3389/fped.2024.1426030.

Construction and experimental verification of a novel nine-glycosylation-related gene prognostic risk model for clear cell renal carcinoma.

Sun W, Guo L, Ye J, Zhou M, Shu C, Ying X Heliyon. 2024; 10(21):e39258.

PMID: 39524749 PMC: 11544054. DOI: 10.1016/j.heliyon.2024.e39258.

DOK1 facilitates the advancement of ccRCC.

Xie W, Zhang Y, Shu B, Zhang Z, Zhang R J Cancer. 2024; 15(19):6213-6222.

PMID: 39513119 PMC: 11540502. DOI: 10.7150/jca.104375.

References

Aerts J, Groener J, Kuiper S, Donker-Koopman W, Strijland A, Ottenhoff R . Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008; 105(8):2812-7. PMC: 2268542. DOI: 10.1073/pnas.0712309105. View

Tu C, Wu M, Lin Y, Kannagi R, Yang R . FUT8 promotes breast cancer cell invasiveness by remodeling TGF-β receptor core fucosylation. Breast Cancer Res. 2017; 19(1):111. PMC: 5629780. DOI: 10.1186/s13058-017-0904-8. View

Tringali C, Lupo B, Silvestri I, Papini N, Anastasia L, Tettamanti G . The plasma membrane sialidase NEU3 regulates the malignancy of renal carcinoma cells by controlling β1 integrin internalization and recycling. J Biol Chem. 2012; 287(51):42835-45. PMC: 3522280. DOI: 10.1074/jbc.M112.407718. View

Oliveira-Ferrer L, Legler K, Milde-Langosch K . Role of protein glycosylation in cancer metastasis. Semin Cancer Biol. 2017; 44:141-152. DOI: 10.1016/j.semcancer.2017.03.002. View

Hatakeyama S, Kyan A, Yamamoto H, Okamoto A, Sugiyama N, Suzuki Y . Core 2 N-acetylglucosaminyltransferase-1 expression induces aggressive potential of testicular germ cell tumor. Int J Cancer. 2009; 127(5):1052-9. PMC: 2897929. DOI: 10.1002/ijc.25117. View

Chauhan S, Ebeling M, Maher D, Koch M, Watanabe A, Aburatani H . MUC13 mucin augments pancreatic tumorigenesis. Mol Cancer Ther. 2011; 11(1):24-33. PMC: 4100478. DOI: 10.1158/1535-7163.MCT-11-0598. View

Bhide G, Colley K . Sialylation of N-glycans: mechanism, cellular compartmentalization and function. Histochem Cell Biol. 2016; 147(2):149-174. PMC: 7088086. DOI: 10.1007/s00418-016-1520-x. View

Carvalho A, Harduin-Lepers A, Magalhaes A, Machado E, Mendes N, Costa L . Differential expression of alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells. Int J Biochem Cell Biol. 2009; 42(1):80-9. DOI: 10.1016/j.biocel.2009.09.010. View

Chen X, Varki A . Advances in the biology and chemistry of sialic acids. ACS Chem Biol. 2009; 5(2):163-76. PMC: 2825284. DOI: 10.1021/cb900266r. View

10.

Miller M, Ma D, Schappet J, Breheny P, Mott S, Bannick N . Downregulation of dystroglycan glycosyltransferases LARGE2 and ISPD associate with increased mortality in clear cell renal cell carcinoma. Mol Cancer. 2015; 14:141. PMC: 4518861. DOI: 10.1186/s12943-015-0416-z. View

11.

Zodro E, Jaroszewski M, Ida A, Wrzesinski T, Kwias Z, Bluyssen H . FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data. Tumour Biol. 2013; 35(3):2607-17. PMC: 3967067. DOI: 10.1007/s13277-013-1344-4. View

12.

Batista L, Matos L, Machado L, Suarez E, Theodoro T, Martins J . Heparanase expression and glycosaminoglycans profile in renal cell carcinoma. Int J Urol. 2012; 19(11):1036-40. DOI: 10.1111/j.1442-2042.2012.03086.x. View

13.

Franco A . Glycoconjugates as vaccines for cancer immunotherapy: clinical trials and future directions. Anticancer Agents Med Chem. 2008; 8(1):86-91. DOI: 10.2174/187152008783330888. View

14.

Pinho S, Seruca R, Gartner F, Yamaguchi Y, Gu J, Taniguchi N . Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol Life Sci. 2010; 68(6):1011-20. PMC: 11114786. DOI: 10.1007/s00018-010-0595-0. View

15.

Theocharis A, Skandalis S, N Tzanakakis G, Karamanos N . Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 2010; 277(19):3904-23. DOI: 10.1111/j.1742-4658.2010.07800.x. View

16.

Larsen R, Nair R, Lowe J . A cloned human cDNA determines expression of a mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase. Genes Dev. 1990; 4(8):1288-303. DOI: 10.1101/gad.4.8.1288. View

17.

Danishefsky S, Shue Y, Chang M, Wong C . Development of Globo-H cancer vaccine. Acc Chem Res. 2015; 48(3):643-52. DOI: 10.1021/ar5004187. View

18.

Audry M, Jeanneau C, Imberty A, Harduin-Lepers A, Delannoy P, Breton C . Current trends in the structure-activity relationships of sialyltransferases. Glycobiology. 2010; 21(6):716-26. DOI: 10.1093/glycob/cwq189. View

19.

Li H, Wang G, Yu Y, Jian W, Zhang D, Wang Y . α-1,2-Mannosidase MAN1C1 Inhibits Proliferation and Invasion of Clear Cell Renal Cell Carcinoma. J Cancer. 2018; 9(24):4618-4626. PMC: 6299394. DOI: 10.7150/jca.27673. View

20.

Becker D, Lowe J . Fucose: biosynthesis and biological function in mammals. Glycobiology. 2003; 13(7):41R-53R. DOI: 10.1093/glycob/cwg054. View